Literature DB >> 19006480

Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

Dushyantha T Jayaweera1, Luis Espinoza, Jose Castro.   

Abstract

BACKGROUND: Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations.
OBJECTIVE: To understand the unique features of etravirine and to evaluate its safety, efficacy, and optimal use.
METHODS: The structure and the mechanism of action of etravirine in blocking the reverse transcriptase enzyme and the preclinical, pharmacokinetic and pharmacodynamic studies were reviewed. The DUET Phase III clinical trials and the resistance profile of etravirine were evaluated.
CONCLUSIONS: Etravirine has unique activity against most HIV isolates that are resistant to other NNRTIs. Unlike other NNRTIs, it has a higher genetic barrier to developing high-grade resistance. In the DUET studies, etravirine demonstrated virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are important drug interactions that will need to be taken into consideration with its use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006480     DOI: 10.1517/14656560802489569

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

1.  In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

2.  Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.

Authors:  Sandra Gonzalez; Damien C Tully; Clement Gondwe; Charles Wood
Journal:  Curr HIV Res       Date:  2013-01       Impact factor: 1.581

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.